DOCSLIB.ORG

Regulation and Function of Heparanase in the Heart

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulation and Function of Heparanase in the Heart Regulation and function of heparanase in the heart by FULONG WANG B.Sc., Southeast University, 2009 M.Sc., University of Chinese Academy of Sciences, 2013 A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE AND POSTDOCTORAL STUDIES (Pharmaceutical Sciences) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) December 2018 © Fulong Wang, 2018 The following individuals certify that they have read, and recommend to the Faculty of Graduate and Postdoctoral Studies for acceptance, the dissertation entitled: Regulation and function of heparanase in the heart submitted Fulong Wang in partial fulfillment of the requirements by for the Doctor of Philosophy degree of in Pharmaceutical Sciences Examining Committee: Brian Rodrigues, Pharmaceutical Sciences Supervisor Dan Luciani, Faculty of Medicine Supervisory Committee Member Bruce Verchere, Faculty of Medicine Supervisory Committee Member Lucy Marzban University Examiner Angela Devlin University Examiner Additional Supervisory Committee Members: David Granville, Faculty of Medicine Supervisory Committee Member Corey Nislow, Pharmaceutical Sciences Supervisory Committee Member ii Abstract Enzymatically-active heparanase (HepA) has been implicated as an essential metabolic adaptation in the heart following diabetes. However, the regulation of the enzymatically- inactive heparanase (HepL) remain poorly understood. We hypothesized that in response to high glucose (HG) and secretion of HepL from the endothelial cell (EC), HepL uptake and function can protect the cardiomyocyte by modifying its cell death signature. HG promoted both HepL and HepA secretion from EC, with subsequent uptake of HepL into cardiomyocytes. This occurred through a low-density lipoprotein receptor-related protein 1 (LRP1) dependent mechanism, as LRP1 inhibition significantly reduced uptake. Exogenous addition of HepL to rat cardiomyocytes produced a dramatically altered expression of apoptosis-related genes, and protection against HG and H2O2 induced cell death. Cardiomyocytes from acutely diabetic rats demonstrated a robust increase in LRP1 expression and levels of heparanase, a pro-survival gene signature, and limited evidence of cell death, observations that were not apparent following chronic and progressive diabetes. We also tested if overexpression of heparanase can protect the heart against chemically induced or ischemia/reperfusion (I/R) injury. Mice overexpressing heparanase (Hep-tg) displayed physiological cardiac hypertrophy and changes in expression of genes related to the stress response, immune response, cell death, and development. These transcriptomic alterations were associated with promotion of unfolded protein response (UPR), autophagy, and oxidative stress resistance in a pro-survival direction. The UPR activation was adaptive and not apoptotic, and together with mTOR inhibition, induced autophagy. Subjecting wild type mice to thapsigargin evoked a transition from adaptive iii to apoptotic UPR, an effect attenuated in Hep-tg hearts. When exposed to I/R, infarct size and apoptosis were significantly lower in the Hep-tg heart, an effect reversed by inhibitors of UPR and autophagy. Our results highlight EC-to-cardiomyocyte transfer of heparanase to modulate the cardiomyocyte cell death signature. This mechanism was observed in the acutely diabetic heart, and its interruption following chronic diabetes may contribute towards the development of diabetic cardiomyopathy. Moreover, we established that the mechanisms by which heparanase promotes cell survival in cancer could be uniquely beneficial to the heart and exploited as a therapeutic target for the treatment of heart disease. iv Lay Summary Heparanase is an enzyme that contributes to the survival of cancer cells under harsh and stressful conditions like radioactive-therapy and chemotherapy and thus contributes towards the aggressiveness of cancer development. The heart cells, contrary to cancer cells, are vulnerable to different types of stresses. This, combined with the limited capability of this organ to regenerate new cells following cell death, leads to the prevalence of heart diseases. We explored the possibility of utilizing the properties of this enzyme to protect cardiac cells against cell death. We found out that heparanase, using its properties to promote cell survival, protected the heart cells against multiple stresses frequently seen in patients with ischemia and diabetes induced heart diseases, in both cell experiments and animal studies. This research could help devise new strategies to combat heart diseases. v Preface This thesis is written by F. Wang and reviewed by Dr. Rodrigues. All the experiments in this thesis were designed and conceived by F. Wang under the supervision of Dr. Rodrigues. Studies in chapter 3 has been previously published (F. Wang, J. Jia, N. Lal, D. Zhang, A. P. Chiu, A. Wan, I. Vlodavsky, B. Hussein, B. Rodrigues. 2016. High glucose facilitated endothelial heparanase transfer to the cardiomyocyte modifies its cell death signature. Cardiovascular Research). F. Wang designed all the experiments and wrote the manuscript with Dr. Rodrigues. D. Zhang, B. Hussein, J. Jia, N. Lal, R. Shang, A. Wan, Y. Wang, and AP. Chiu participated in data analysis and manuscript editing. Dr. Vlodavsky provided the recombinant heparanase. Data in chapter 4 is currently submitted (Fulong Wang, Yanzhi Carolyn Jia, Dahai Zhang, Boris Trinajstic, Jocelyn Jia, Nathaniel Lal, Karn Puri, Rui Shang, Stephane Flibotte, Sunita Sinha, Purvi Trivedi, Dipsikha Biswas, Kathleen Macleod, Corey Nislow, Israel Vlodavsky, Thomas Pulinilkunnil, Bahira Hussein, and Brian Rodrigues. 2018. Heparanase Overexpression Protects Mouse Heart against Chemical or Ischemia/Reperfusion Injury. Submitted). D. Zhang, B. Hussein, J. Jia, N. Lal, R. Shang, A. Wan, Y. Wang, and AP. Chiu contributed in editing the manuscript. S. Flibotte and S. Sinha performed the RNAseq of ventricle and analyzed the data. YZ-C. Jia performed the echocardiology. Dr. Vlodavsky provided the heparanase transgenic mice. Dr. Pulinilkunnil assisted in conceiving some of the experiments and did part of the ischemia/reperfusion experiments. B. Hussein provided assistance with monitoring the animals, technical support and editing the manuscript. The study conforms to the guide for the care and use of laboratory animals published by the US National Institutes of Health, and was approved vi by the Animal Care Committee in the University of British Columbia (Certificate No. A13- 0250). vii Table of Contents Abstract ........................................................................................................................................... iii Lay Summary .................................................................................................................................... v Preface ............................................................................................................................................ vi Table of Contents .......................................................................................................................... viii List of Tables ................................................................................................................................... xi List of Figures ................................................................................................................................. xii List of Abbreviations and Acronyms ............................................................................................ xiv Acknowledgements .................................................................................................................... xviii Chapter 1: Introduction .................................................................................................................. 1 1.1 Heparan sulfate proteoglycans (HSPGs) ..................................................................... 1 1.2 Heparanase .................................................................................................................. 2 1.3 Heart disease ............................................................................................................... 5 1.3.1 Heart disease ............................................................................................... 5 1.3.2 Diabetic cardiomyopathy (DCM) ................................................................. 6 1.3.3 Ischemic heart diseases ............................................................................... 6 1.4 Unfolded protein response (UPR) and heart disease ................................................. 9 1.4.1 UPR ............................................................................................................... 9 1.4.1 UPR and heart diseases ............................................................................. 12 1.5 Heart disease and autophagy .................................................................................... 14 1.5.1 Introduction ............................................................................................... 14 1.5.2 Processes of autophagy ............................................................................. 15 1.5.3 Regulation of autophagy ........................................................................... 17 1.5.4 Physiological and pathophysiological roles of autophagy ....................... 18 1.5.5 The balance between autophagy and apoptosis .....................................
Load more

Recommended publications
  • Localization of Heparanase in Esophageal Cancer Cells: Respective Roles in Prognosis and Differentiation
    Laboratory Investigation (2004) 84, 1289–1304 & 2004 USCAP, Inc All rights reserved 0023-6837/04 $30.00 www.laboratoryinvestigation.org Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation Takaomi Ohkawa1, Yoshio Naomoto1, Munenori Takaoka1, Tetsuji Nobuhisa1, Kazuhiro Noma1, Takayuki Motoki1, Toshihiro Murata1, Hirokazu Uetsuka1, Masahiko Kobayashi1, Yasuhiro Shirakawa1, Tomoki Yamatsuji1, Nagahide Matsubara1, Junji Matsuoka1, Minoru Haisa1, Mehmet Gunduz2, Hidetsugu Tsujigiwa2, Hitoshi Nagatsuka2, Masao Hosokawa3, Motowo Nakajima4 and Noriaki Tanaka1 1Department of Gastroenterological Surgery, Transplant, and Surgical Oncology; 2Department of Oral Pathology and Medicine, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan; 3Keiyukai Sapporo Hospital, Sapporo, Japan and 4Tsukuba Research Institute, Novartis Pharma KK Tsukuba, Japan In this study, we examined the distribution of heparanase protein in 75 esophageal squamous cell carcinomas by immunohistochemistry and analyzed the relationship between heparanase expression and clinicopatho- logical characteristics. In situ hybridization showed that the mRNA expression pattern of heparanase was similar to that of the protein, suggesting that increased expression of the heparanase protein at the invasive front was caused by an increase of heparanase mRNA in tumor cells. Heparanase expression correlated significantly with depth of tumor invasion, lymph node metastasis, tumor node metastasis (TNM) stage and lymphatic
    [Show full text]
  • Ultrasensitive Small Molecule Fluorogenic Probe for Human Heparanase
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.26.008730; this version posted March 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Ultrasensitive small molecule fluorogenic probe for human heparanase Jun Liu1, 2, Kelton A. Schleyer1, 2, Tyrel L. Bryan2, Changjian Xie2, Gustavo Seabra1, Yongmei Xu3, Arjun Kafle2, Chao Cui1, 2, Ying Wang2, Kunlun Yin2, Benjamin Fetrow2, Paul K. P. Henderson2, Peter Z. Fatland2, Jian Liu3, Chenglong Li1, Hua Guo2, and Lina Cui1, 2, * 1Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA (Current) 2Department of Chemistry and Chemical Biology, University of New Mexico, Albuquerque, NM 87131, USA 3Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA *Correspondence should be addressed to L.C. E-mail: [email protected] Abstract Heparanase is a critical enzyme involved in the remodeling of the extracellular matrix (ECM), and its elevated expression has been linked with diseases such as cancer and inflammation. The detection of heparanase enzymatic activity holds tremendous value in the study of the cellular microenvironment, and search of molecular therapeutics targeting heparanase, however, assays developed for this enzyme so far have suffered prohibitive drawbacks. Here we present an ultrasensitive fluorogenic small-molecule probe for heparanase enzymatic activity. The probe exhibits a 756-fold fluorescence turn-on response in the presence of human heparanase, allowing one-step detection of heparanase activity in real-time with a picomolar detection limit.
    [Show full text]
  • Heparanase Is Required for Activation and Function of Macrophages
    Heparanase is required for activation and function of macrophages Lilach Gutter-Kapona, Dror Alishekevitzb, Yuval Shakedb, Jin-Ping Lic, Ami Aronheimd, Neta Ilana, and Israel Vlodavskya,1 aCancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel; bDepartment of Cell Biology and Cancer Science, Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel; cDepartment of Medical Biochemistry and Microbiology, University of Uppsala, SE-751 05 Uppsala, Sweden; and dDepartment of Molecular Genetics, the Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel Edited by Joseph Schlessinger, Yale University School of Medicine, New Haven, CT, and approved October 17, 2016 (received for review July 13, 2016) The emerging role of heparanase in tumor initiation, growth, The carcinoma microenvironment includes nontransformed metastasis, and chemoresistance is well recognized and is encouraging epithelial cells, fibroblasts, endothelial cells, and infiltrated immune the development of heparanase inhibitors as anticancer drugs. Unlike cells. Endothelial cells lining blood and lymph vessels are major the function of heparanase in cancer cells, very little attention has component of the tumor microenvironment, and antiangiogenesis been given to heparanase contributed by cells composing the tumor therapy, targeting vascular endothelial growth factor (VEGF) or microenvironment. Here we used a genetic approach and examined its receptor (VEGFR2), is implemented clinically (15). In addi- the behavior and function of macrophages isolated from wild-type tion, recent research has revealed the critical roles of inflam- (WT) and heparanase-knockout (Hpa-KO) mice. Hpa-KO macrophages matory responses in different stages of tumor development and express lower levels of cytokines (e.g., TNFα,IL1-β) and exhibit lower metastasis (16).
    [Show full text]
  • Trevigen Price List 2008 International.Indd
    BASEMENT MEMBRANE EXTRACT PRODUCTS AND SPECIALTY PROTEINS • CELL INVASION ASSAYS • DIRECTED IN VIVO ANGIOGENESIS ASSAYS • COMETASSAYTM • TREVIGEN PAR/PARP/PARG • PRODUCT FOCUS and price list 2008-2009MAY 2008 TACSTM IN SITU APOPTOSIS DETECTION KITS • 1.800.TREVIGEN • www.trevigen.com 2008 TREVIGEN PRODUCT FOCUS AND PRICE LIST Product Overviews BME Tools for 3D Culture Assays TACS™ Basement Membrane Extract Products and 3D Culture Cell Proliferation Assay (96 well) .......10 In Situ Apoptosis Detection Kits .....................18-23 Specialty Proteins ............................................2-5 3D Culture Cell Harvesting Kit ............................11 Annexin DIVAA™ PAR/PARP/PARG For monitoring apoptosis via flow cytometry ...24-25 Directed in vivo Angiogenesis Assays .................6-7 Kits, Reagents, Antibodies, and Enzymes .......12-14 Oxidative Stress Kits Cell Invasion/Migration Assays CometAssay™ ..................................................................26-27 Kits, Reagents, and Plates ................................8-9 Kits, Reagents, and Slides ............................15-17 Trevigen Product International Cell Assays ......................................25 Price List ..........................................28-38 Distributors ..............................39-40 Ordering Information • Please use product names and catalog numbers when ordering. Conditions Trevigen products are sold for Research Use Only. • Please provide your name, purchase order number, shipping address, billing address, and telephone number
    [Show full text]
  • Evidence Against a Role for Heparan Sulfate in Glomerular Permselectivity
    JASN Express. Published on February 14, 2007 as doi: 10.1681/ASN.2007010086 Editorial Breaking Down the Barrier: Evidence against a Role for Heparan Sulfate in Glomerular Permselectivity Scott J. Harvey and Jeffrey H. Miner Renal Division, Washington University School of Medicine, St. Louis, Missouri J Am Soc Nephrol 18: 672–674, 2007. doi: 10.1681/ASN.2007010086 he glomerular capillary wall is thought to function as Charge barrier dysfunction has long been touted as an un- both a size- and charge-selective barrier. The concept of derlying cause of human glomerular disease (10–12). This may T charge selectivity emerged from a series of now classic be brought about by decreased expression or undersulfation of studies that used tracers such as dextran, peroxidase, and fer- GBM-HSPG (13,14). Segmental or global loss of GBM-HS has ritin to evaluate the influence of molecular charge on glomer- been reported in human membranous nephritis, lupus nephri- ular filtration (1–5). The permeability of anionic derivatives of tis, minimal change disease, and diabetic nephropathy (13,15), each tracer was lower than their neutral counterparts of com- as well as in rat models of adriamycin and Heymann nephritis parable size, whereas the permeability of cationic forms was (16,17). The intensity of GBM labeling inversely correlates with enhanced. This led to the theory that the passage of endoge- severity of disease, which supports the theory that reductions nous circulating polyanions, notably albumin, would likewise in GBM-HS contribute directly to a loss of barrier function. be impeded by the “fixed” or intrinsic negative charge of the However, in a recent study, GBM-HS was reported to be nor- glomerular capillary wall.
    [Show full text]
  • Extracellular Matrix Degrading Enzymes at the Prostasome Surface
    Prostate Cancer and Prostatic Diseases (2005) 8, 344–348 & 2005 Nature Publishing Group All rights reserved 1365-7852/05 $30.00 www.nature.com/pcan Extracellular matrix degrading enzymes at the prostasome surface I Bellezza1, MC Aisa2, R Palazzo1, E Costanzi1, E Mearini3 & A Minelli1* 1Dipartimento Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, Perugia, Italy; 2Dipartimento Medicina Interna, Sezione Biochimica Applicata Scienze Nutrizionali, Perugia, Italy; and 3Diparimento Specialita` Chirurgiche, Sezione di Urologia, Universita` di Perugia, Perugia, Italia Prostasomes, prostatic secretory vesicles found in human ejaculates, were analyzed to verify the existence at their surfaces of enzymes involved in the degradation of the extracellular matrix. Findings were compared with those of prostasomes isolated from two human adenocarcinoma cell lines that reflect clinical features and molecular pathways of androgen-insensitive and hormone-responsive prostate cancer. Our aim was to determine whether neoplastic transformation is accompanied by changes of glycosidase and protease activities. Our results show that decreases of dipeptidyl peptidase IV and increases of urokinase plasminogen activator and cathepsin B are consistent with the clinical features of the cell lines, whereas increases of glycosidase activities seem to be of scarce biological significance. Prostate Cancer and Prostatic Diseases (2005) 8, 344–348. doi:10.1038/sj.pcan.4500828; published online 30 August 2005 Keywords: PC3; LNCaP; glycosidases; proteases Introduction istics and the presence of saturated and monounsatu- rated fatty acids make the prostasome membrane highly The human prostate gland has a remarkably high ordered and rigid.1 A proteomic analysis has shown the incidence of neoplastic disease and prostate cancer is existence at the prostasome surface of at least 139 one of the most commonly detected male cancers that proteins including enzymes (35%), transport/structural result in a high incidence of mortality.
    [Show full text]
  • Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by a Readily Released Heparanase from Human Neutrophils
    Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. Y Matzner, … , Z Fuks, I Vlodavsky J Clin Invest. 1985;76(4):1306-1313. https://doi.org/10.1172/JCI112104. Research Article Freshly isolated human neutrophils were investigated for their ability to degrade heparan sulfate proteoglycans in the subendothelial extracellular matrix (ECM) produced by cultured corneal and vascular endothelial cells. The ECM was metabolically labeled with Na2(35S)O4 and labeled degradation products were analyzed by gel filtration over Sepharose 6B. More than 90% of the released radioactivity consisted of heparan sulfate fragments 5-6 times smaller than intact heparan sulfate side chains released from the ECM by either papain or alkaline borohydride. These fragments were sensitive to deamination with nitrous acid and were not produced in the presence of either heparin or serine protease inhibitors. In contrast, degradation of soluble high molecular weight heparan sulfate proteoglycan, which was first released from the ECM, was inhibited by heparin but there was no effect of protease inhibitors. These results indicate that interaction of human neutrophils with the subendothelial ECM is associated with degradation of its heparan sulfate by means of a specific, newly identified, heparanase activity and that this degradation is facilitated to a large extent by serine proteases. The neutrophil heparanase was readily and preferentially
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,689,046 B2 Mayall Et Al
    USOO9689046B2 (12) United States Patent (10) Patent No.: US 9,689,046 B2 Mayall et al. (45) Date of Patent: Jun. 27, 2017 (54) SYSTEM AND METHODS FOR THE FOREIGN PATENT DOCUMENTS DETECTION OF MULTIPLE CHEMICAL WO O125472 A1 4/2001 COMPOUNDS WO O169245 A2 9, 2001 (71) Applicants: Robert Matthew Mayall, Calgary (CA); Emily Candice Hicks, Calgary OTHER PUBLICATIONS (CA); Margaret Mary-Flora Bebeselea, A. et al., “Electrochemical Degradation and Determina Renaud-Young, Calgary (CA); David tion of 4-Nitrophenol Using Multiple Pulsed Amperometry at Christopher Lloyd, Calgary (CA); Lisa Graphite Based Electrodes', Chem. Bull. “Politehnica” Univ. Kara Oberding, Calgary (CA); Iain (Timisoara), vol. 53(67), 1-2, 2008. Fraser Scotney George, Calgary (CA) Ben-Yoav. H. et al., “A whole cell electrochemical biosensor for water genotoxicity bio-detection”. Electrochimica Acta, 2009, 54(25), 6113-6118. (72) Inventors: Robert Matthew Mayall, Calgary Biran, I. et al., “On-line monitoring of gene expression'. Microbi (CA); Emily Candice Hicks, Calgary ology (Reading, England), 1999, 145 (Pt 8), 2129-2133. (CA); Margaret Mary-Flora Da Silva, P.S. et al., “Electrochemical Behavior of Hydroquinone Renaud-Young, Calgary (CA); David and Catechol at a Silsesquioxane-Modified Carbon Paste Elec trode'. J. Braz. Chem. Soc., vol. 24, No. 4, 695-699, 2013. Christopher Lloyd, Calgary (CA); Lisa Enache, T. A. & Oliveira-Brett, A. M., "Phenol and Para-Substituted Kara Oberding, Calgary (CA); Iain Phenols Electrochemical Oxidation Pathways”, Journal of Fraser Scotney George, Calgary (CA) Electroanalytical Chemistry, 2011, 1-35. Etesami, M. et al., “Electrooxidation of hydroquinone on simply prepared Au-Pt bimetallic nanoparticles'. Science China, Chem (73) Assignee: FREDSENSE TECHNOLOGIES istry, vol.
    [Show full text]
  • 1994 De Vouge MW, Yamazaki A, Bennett SAL, Chen JH, Shwed PS
    Int. J. Cancer: 56,286-294 (1994) Publication of the International Union Against Cancer Publication de I Union Internattonale Contre le Cancer 0 1994 Wiley-Liss, Inc. a' IMMUNOSELECTION OF GRP94/ENDOPLASMIN FROM A KNRK CELL-SPECIFIC Xgt 11 LIBRARY USING ANTIBODIES DIRECTED AGAINST A PUTATIVE HEPARANASE AMINO-TERMINAL PEPTIDE Michael W. DE VOUGE',Amy YAMAZAKI~,Steffany A.L. BENNETT',Jia-Hua CHEN'4, Philip S. SHWED'2, Chantal COUTURE' and H. Chaim BIRNBOIM1,3 'Ottawa Regional Cancer Centre and University of Ottawa, 501 Smyth Road, Ottawa, Ontario, KlH 8L6, Canada. Induction of an invasive phenotype by metastatic tumour cells Enhanced release of HS fragments from Na2[35S04]-labeled results in part from inappropriate expression of extracellular extracellular matrix was initially correlated with metastatic matrix-degradingenzymes normally involved in embryonic mor- potential in cellular extracts, but not in conditioned media, of phogenesis, tissue remodelling, angiogenesis and wound heal- B16 murine melanoma clones (Nakajima et al., 1983). Analyses ing. Such enzymes include endoglycosidases that degrade hepa- of substrate specificity, and examination of reducing termini of ran sulfate (HS) in endothelial basement membrane, as well as better characterized proteases. Heparanase, an endo-P-D- HS fragments led to the characterization of heparanase as an glucuronidase initially detected in B I6 melanoma cells, has endo-P-D-glucuronidase that is inhibited by heparin (Na- been described as a M, 96 000 glycoprotein with pl of 5.2, and kajima et al.,
    [Show full text]
  • Acid Phosphatase 5 Is Responsible for Removing the Mannose 6-Phosphate Recognition Marker from Lysosomal Proteins
    Acid phosphatase 5 is responsible for removing the mannose 6-phosphate recognition marker from lysosomal proteins Pengling Suna, David E. Sleata, Miche` le Lecocqb, Alison R. Haymanc, Michel Jadotb, and Peter Lobela,1 aCenter for Advanced Biotechnology and Medicine and Department of Pharmacology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, NJ 08854; bLaboratoire de Chimie Physiologique, Unite´de Recherche en Physiologie Mole´culaire, Faculte´s Universitaires Notre-Dame de la Paix, 61 rue de Bruxelles, 5000-Namur, Belgium; and cSchool of Clinical Veterinary Science, University of Bristol, Bristol BS40 5DU, UK Edited by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, and approved September 12, 2008 (received for review July 31, 2008) Most newly synthesized proteins destined for the lysosome reach Golgi to repeat the process or to the plasma membrane. At the this location via a specific intracellular pathway. In the Golgi, a latter location, the CI-MPR can function in the endocytosis and phosphotransferase specifically labels lysosomal proteins with lysosomal targeting of extracellular Man-6-P glycoproteins. mannose 6-phosphate (Man-6-P). This modification is recognized Early studies indicated that Man-6 phosphorylation was a by receptors that target the lysosomal proteins to the lysosome transient modification of lysosomal proteins that was removed where, in most cell types, the Man-6-P recognition marker is rapidly with a half-life of 1.4 h in mouse lymphoma cells (3) and also removed. Despite extensive characterization of this pathway, the rapidly removed in CHO cells (4). The exact site of dephos- enzyme responsible for the removal of the targeting modification phorylation is not clear, and there is evidence suggesting that it has remained elusive.
    [Show full text]
  • In Vivo Fragmentation of Heparan Sulfate by Heparanase Overexpression Renders Mice Resistant to Amyloid Protein a Amyloidosis
    In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis Jin-Ping Li*†, Martha L. Escobar Galvis*‡, Feng Gong*‡§, Xiao Zhang¶, Eyal Zchariaʈ, Shula Metzger**, Israel Vlodavsky††, Robert Kisilevsky‡‡, and Ulf Lindahl* *Department of Medical Biochemistry and Microbiology, Biomedical Center, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden; ¶Department of Public Health and Caring Science, Division of Molecular Geriatrics, Rudbeck Laboratory, Uppsala University, Box 609, SE-751 25 Uppsala, Sweden; Departments of ʈOncology and **Medicine, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel; ††Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel; and ‡‡Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada K7L 3N6 Communicated by D. Carleton Gajdusek, Centre National de la Recherche Scientifique, Gif-sur-Yvette, France, March 21, 2005 (received for review December 22, 2004) Amyloid diseases encompass >20 medical disorders that include The results demonstrate that overexpression of heparanase, amyloid protein A (AA) amyloidosis, Alzheimer’s disease, and type resulting in fragmentation of HS chains, affords protection 2 diabetes. A common feature of these conditions is the selective against amyloidosis. organ deposition of disease-specific fibrillar proteins, along with the sulfated glycosaminoglycan, heparan sulfate. We have gener- Materials and Methods ated transgenic mice that overexpress human heparanase and Animals and Amyloid Induction. The homozygous mouse strain have tested their susceptibility to amyloid induction. Drastic short- overexpressing human heparanase (hpa-tg) and the respective ening of heparan sulfate chains was observed in heparanase- control (ctr) mice (C57BL background) were generated as overproducing organs, such as liver and kidney.
    [Show full text]
  • 1 Novel Expression Signatures Identified by Transcriptional Analysis
    ARD Online First, published on October 7, 2009 as 10.1136/ard.2009.108043 Ann Rheum Dis: first published as 10.1136/ard.2009.108043 on 7 October 2009. Downloaded from Novel expression signatures identified by transcriptional analysis of separated leukocyte subsets in SLE and vasculitis 1Paul A Lyons, 1Eoin F McKinney, 1Tim F Rayner, 1Alexander Hatton, 1Hayley B Woffendin, 1Maria Koukoulaki, 2Thomas C Freeman, 1David RW Jayne, 1Afzal N Chaudhry, and 1Kenneth GC Smith. 1Cambridge Institute for Medical Research and Department of Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK 2Roslin Institute, University of Edinburgh, Roslin, Midlothian, EH25 9PS, UK Correspondence should be addressed to Dr Paul Lyons or Prof Kenneth Smith, Department of Medicine, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK. Telephone: +44 1223 762642, Fax: +44 1223 762640, E-mail: [email protected] or [email protected] Key words: Gene expression, autoimmune disease, SLE, vasculitis Word count: 2,906 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Annals of the Rheumatic Diseases and any other BMJPGL products to exploit all subsidiary rights, as set out in their licence (http://ard.bmj.com/ifora/licence.pdf). http://ard.bmj.com/ on September 29, 2021 by guest. Protected copyright. 1 Copyright Article author (or their employer) 2009.
    [Show full text]